The FDA's approval of durvalumab for LS-SCLC represents a pivotal shift in the standard of care (SOC) for this cancer type, which had seen little change over the past 30 years. The phase 3 ADRIATIC trial demonstrated that durvalumab significantly improved overall survival (OS) and progression-free survival (PFS) compared to placebo in patients who did not experience disease progression following concurrent platinum-based chemoradiotherapy.
Key findings from the ADRIATIC trial include a median OS of 55.9 months with durvalumab versus 33.4 months with placebo, and a median PFS of 16.6 months versus 9.2 months, respectively. The trial also highlighted the safety profile of durvalumab, with the most common adverse effects being pneumonitis or radiation pneumonitis, fatigue, and rash. Despite these, the treatment was well tolerated over a period of up to 2 years.
This approval addresses the unmet need for improved survival rates in LS-SCLC, offering a new hope for patients. The success of durvalumab in this setting is attributed to the priming of the tumor microenvironment by prior thoracic chemoradiotherapy, making it more susceptible to immunotherapy. Ongoing research, including the NRG-LU005 trial, continues to explore the potential of immunotherapy in LS-SCLC, though initial findings suggest that the timing and duration of immunotherapy administration are crucial factors in its efficacy.
